(LAB) Standard Biotools - Ratings and Ratios

Standard BioTools Inc. (NASDAQ:LAB), formerly Fluidigm Corporation, is a leading provider of life sciences tools and services, operating globally across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region. The company specializes in delivering advanced instruments, consumables, reagents, and software solutions for researchers and clinical laboratories. Its product portfolio is divided into two primary segments: Proteomics and Genomics.

In the Proteomics segment, the company offers high-parameter single-cell analysis systems such as the CyTOF XT System, which utilizes metal isotope-conjugated antibodies for automated single-cell analysis. Additionally, the Hyperion XTi Imaging System is a spatial biology instrument designed for high-resolution tissue imaging. These systems are widely adopted in academic research institutions, translational medicine centers, and biopharmaceutical companies.

The Genomics segment includes real-time PCR systems like the X9 Real-Time PCR System and the Biomark HD System, both of which integrate microfluidics-based workflows using proprietary Integrated Fluidic Circuit (IFC) technology. The company also provides IFC Controllers, which are essential for operating IFC formats in genomic analysis. These products are critical for applications in cancer research, clinical laboratories, and contract research organizations.

Standard BioTools has strategic license agreements with prestigious institutions such as California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company, rebranded from Fluidigm Corporation in April 2022, was originally incorporated in 1999 and is headquartered in South San Francisco, California. Its products are sold to a diverse customer base, including academic research institutions, biotechnology firms, and clinical laboratories.

From a financial perspective, the company has a market capitalization of $469.05 million USD, with a price-to-book (P/B) ratio of 1.01, indicating its assets are valued near their book value. The price-to-sales (P/S) ratio of 3.01 reflects moderate revenue multiples. However, the return on equity (RoE) stands at -25.46%, highlighting ongoing profitability challenges.